Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader

Company Overview - Boundless Bio (BOLD) is a biotech company focused on developing treatments for oncology by targeting ecDNA (extrachromosomal DNA)-dependent tumors [1] - The company's lead clinical-stage asset is BBI-940, which aims to eliminate ecDNA from cancer cells [1] Investment Focus - The investment style is centered on clinical-stage biotech stocks, with a focus on both long-term ideas and event-driven trading [1] - The analyst involved has a background in clinical research, which aids in evaluating the scientific fundamentals of biotech stocks [1]